Table 3. Multivariate analyses of the correlation between SNPs and treatment efficacy at the end of radiotherapy.
SNPs | Genotypes | Primary tumor efficacy1 (n=174) | Lymph node efficacy1 (n=144) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CR2 | Non-CR2 | OR | 95%CI | P | CR2 | Non-CR2 | OR | 95%CI | P | ||
XRCC1 rs25489 | GG:GA | 111/25/4 | 18/14/2 | 3.833 | 1.512-9.714 | 0.005 | 95/26/4 | 15/4/0 | 0.818 | 0.199-3.358 | 0.780 |
GG:AA | 2.552 | 0.360-18.088 | 0.348 | - | - | - | |||||
GG:(GA+AA) | 3.610 | 1.496-8.713 | 0.004 | 0.699 | 0.174-2.813 | 0.615 | |||||
(GG+GA):AA | 1.764 | 0.257-12.110 | 0.564 | - | - | - | |||||
OGG1 rs1052133 | CC:CG | 42/68/30 | 15/15/4 | 0.552 | 0.227-1.344 | 0.191 | 45/58/22 | 5/9/5 | 1.922 | 0.518-7.128 | 0.329 |
CC:GG | 0.263 | 0.073-0.951 | 0.042 | 2.832 | 0.605-13.252 | 0.186 | |||||
CC:(CG+GG) | 0.454 | 0.195-1.053 | 0.066 | 2.161 | 0.629-7.430 | 0.221 | |||||
(CC+CG):GG | 0.371 | 0.114-1.209 | 0.100 | 1.895 | 0.532-6.745 | 0.324 | |||||
APE(X)1 rs1130409 | TT:TG | 51/74/15 | 17/14/3 | 0.853 | 0.348-2.088 | 0.728 | 47/65/13 | 9/8/2 | 0.592 | 0.179-1.963 | 0.392 |
TT:GG | 0.392 | 0.088-1.749 | 0.220 | 0.698 | 0.107-4.570 | 0.708 | |||||
TT:(TG+GG) | 0.719 | 0.310-1.667 | 0.442 | 0.615 | 0.203-1.865 | 0.390 | |||||
(TT+TG):GG | 0.420 | 0.099-1.786 | 0.240 | 0.862 | 0.139-5.331 | 0.873 |
1 Adjusted for age, gender, drinking, smoking, family history, BMI, TNM stage, clinical stage, treatment and EBV-DNA.
2 Wild homozygote / heterozygote / mutant homozygote.
SNPs, single nucleotide polymorphisms; CR, complete remission; OR, odds ratio; 95%CI, 95% confidence interval.
P values < 0.05 are shown in bold.